{"id":"protopic-r","safety":{"commonSideEffects":[{"rate":"10–50","effect":"Application site burning or irritation"},{"rate":"5–15","effect":"Pruritus"},{"rate":"5–10","effect":"Skin erythema"},{"rate":"1–5","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL89731","moleculeType":"Small molecule","molecularWeight":"159.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to FKBP12 and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT transcription factors. This blocks T-cell proliferation and the production of inflammatory cytokines (IL-2, TNF-α, IFN-γ) that drive atopic dermatitis and other inflammatory skin conditions. The topical formulation allows localized immunosuppression with reduced systemic exposure.","oneSentence":"Protopic (tacrolimus) is a calcineurin inhibitor that suppresses T-cell activation and cytokine production to reduce inflammatory skin responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:59.309Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis (eczema)"},{"name":"Other inflammatory skin conditions (off-label use in vitiligo, psoriasis)"}]},"trialDetails":[{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT06033196","phase":"PHASE2","title":"Tocilizumab in Lung Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"Lung Transplant","enrollment":350},{"nctId":"NCT07430683","phase":"PHASE4","title":"Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Guadalajara","startDate":"2024-03-01","conditions":"Cytomegalovirus Infections","enrollment":68},{"nctId":"NCT06291103","phase":"PHASE2, PHASE3","title":"Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-03-01","conditions":"Kidney Transplant Rejection","enrollment":290},{"nctId":"NCT03467386","phase":"PHASE1","title":"Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2018-03-19","conditions":"Acute Myeloid Leukemia","enrollment":56},{"nctId":"NCT07297173","phase":"PHASE1","title":"Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-12-01","conditions":"Relapsed Leukemia, Refractory Leukemia","enrollment":5},{"nctId":"NCT03247088","phase":"PHASE1, PHASE2","title":"Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-30","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":74},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT04725682","phase":"PHASE1","title":"Bioequivalence Study of Tacrolimus in Healthy Volunteers","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2021-01-05","conditions":"Healthy Volunteers","enrollment":67},{"nctId":"NCT01256398","phase":"PHASE2","title":"Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12-14","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":66},{"nctId":"NCT02960646","phase":"PHASE1","title":"Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-01-18","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":11},{"nctId":"NCT01028716","phase":"PHASE2","title":"Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-05-19","conditions":"Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission","enrollment":46},{"nctId":"NCT05532111","phase":"NA","title":"Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2022-09-01","conditions":"Efficacy and Safety","enrollment":60},{"nctId":"NCT00919503","phase":"PHASE2","title":"Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-07-31","conditions":"Non-Neoplastic Hematologic and Lymphocytic Disorder","enrollment":98},{"nctId":"NCT03426969","phase":"EARLY_PHASE1","title":"Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-01-31","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":3},{"nctId":"NCT01629511","phase":"PHASE1, PHASE2","title":"Allogeneic Stem Cell Transplant for CLL","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-11-21","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia","enrollment":15},{"nctId":"NCT00973804","phase":"PHASE1","title":"Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-08-25","conditions":"Leukemia, Non-Hodgkins Lymphoma, Hodgkins Lymphoma","enrollment":4},{"nctId":"NCT00439556","phase":"PHASE2","title":"Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-02-13","conditions":"CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Lymphocytic Neoplasm","enrollment":40},{"nctId":"NCT00880815","phase":"PHASE1","title":"Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-02-17","conditions":"CD20 Positive, Chronic Lymphocytic Leukemia, Follicular Lymphoma","enrollment":60},{"nctId":"NCT02084446","phase":"PHASE4","title":"Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant","status":"COMPLETED","sponsor":"Ronaldo de Matos Esmeraldo, MD","startDate":"2012-12","conditions":"Transplantation Infection, Cytomegalovirus Infections","enrollment":120},{"nctId":"NCT02004860","phase":"PHASE3","title":"Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2014-01","conditions":"Severe Seborrheic Dermatitis","enrollment":120},{"nctId":"NCT02199041","phase":"PHASE2","title":"Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-07-11","conditions":"Hematological Malignancies","enrollment":24},{"nctId":"NCT00899847","phase":"PHASE2","title":"Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-05","conditions":"Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma","enrollment":9},{"nctId":"NCT01621477","phase":"PHASE2","title":"T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia","enrollment":34},{"nctId":"NCT02963103","phase":"PHASE4","title":"A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen","status":"TERMINATED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2010-05","conditions":"Kidney Transplantation","enrollment":13},{"nctId":"NCT01467505","phase":"PHASE2","title":"An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Hepatitis C","enrollment":61},{"nctId":"NCT00360685","phase":"NA","title":"Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2005-09","conditions":"Mucositis, Graft-versus-host Disease","enrollment":89},{"nctId":"NCT00621699","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects","status":"COMPLETED","sponsor":"University Medicine Greifswald","startDate":"2007-09","conditions":"Pharmacokinetics, Drug Interactions, Hypercholesterolemia","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tacrolimus"],"phase":"phase_3","status":"active","brandName":"Protopic (R)","genericName":"Protopic (R)","companyName":"University Hospital, Rouen","companyId":"university-hospital-rouen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Protopic (tacrolimus) is a calcineurin inhibitor that suppresses T-cell activation and cytokine production to reduce inflammatory skin responses. Used for Atopic dermatitis (eczema), Other inflammatory skin conditions (off-label use in vitiligo, psoriasis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}